Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

• the present invention relates to the field of gene therapy.
• Various diseases originate from defective genes that are either inherited or modified during life by environmental agents. Examples of these diseases include different forms of cancer, hemophilia, or LDL receptor deficiency. Gene therapy or gene replacement therapy promises a fundamental cure for these diseases by replacing, augmenting, or inhibiting these defective genes.
• Common vectors for introducing the therapeutic gene or nucleic acid include viral and non- viral vectors. Although viral delivery systems have been considered to be most efficient in delivering genes to cells, it may be limited because of a risk of triggering inflammatory or immunogenic responses. Forbes, S.J., Review Article: Gene Therapy in Gastroenterology and Hepatology, Aliment Pharmacol. Ther. 11:823-826 (1997).
• adenoviral vectors offer several advantages over other viral vectors in that they can infect a wide range of cells and are not limited to replicating cells, as are retroviral vectors, adenoviral vectors may activate the immune system, as seen in the Gelsinger' s case, such that the initial dose or repeated introduction may become less effective, if not life threatening. See also Forbes, S.J., supra.
• the potential immune response to gene therapy is not limited to the vector used. Since the vector introduces a genetic sequence that encodes a protein, polypeptide, enzyme that may be seen as "foreign" to the host, immune responses toward the cells expressing that sequence and the products of that expression limit the effectiveness of the therapy. For example, in hemophilia experiments using the Factor VIII or DC gene as the therapeutic gene, antibodies generated against the newly expressed proteins may limit the effectiveness of the therapy. Forbes, S.J., supra; see also Herzog, R., Problems and Prospects in Gene Therapy for Hemophilia, Current Opinions in Hematology. 5:321-326 (1998). Cytotoxic T cells such as neutrophils may also attack these cells that expressed the "foreign" genes or viral vector genes, again limiting the effectiveness of gene therapy over a sustained period of time.
• the present invention involves the use of alpha-MSH and/or its derivatives as an adjunct to gene therapy.
• the gene therapy vector includes nucleic-acid sequences that express alpha-MSH and/or its derivatives, and inflammatory or immune-response gene promoters may control their expression. The sequences may also be expressed together with a therapeutic gene using an internal ribosomal entry site sequence.
• pharmacologically effective amount of alpha-MSH and/or its derivatives may be administered before, after, and/or concurrently with the gene therapy vector carrying the appropriate gene.
• the present invention involves a method and system for gene therapy using alpha- melanocyte stimulating hormone (" ⁇ -MSH”) and/or its derivatives as an adjunct therapy. Because of its anti-inflammatory and anti-pyretic activities, ⁇ -MSH and/or its derivatives may supplement gene therapy applications by limiting the inflammatory response of the patients to the gene therapy vector or the expressed protein. Unlike other immunosuppressants, ⁇ -MSH and/or its derivatives also possess antimicrobial properties that may simultaneously protect the body against infection and limit the negative effects of the immune system.
• ⁇ -MSH alpha- melanocyte stimulating hormone
• a pharmacologically effective amount of ⁇ -MSH and/or its derivatives may be administered before or after the gene therapy vector carrying the appropriate therapeutic gene or nucleic acid is administered.
• ⁇ -MSH and/or its derivatives may also be administered together with the gene therapy vector as a cocktail.
• the gene therapy vector may include both viral vectors such as adenoviral, retroviral, lentiviral, or adenovirus-associated viral (AAN) vectors, and non-viral vectors such as liposomes, calcium phosphate, antibodies or receptor based transfer vectors, electroporation, or direct injection of nucleic acids.
• the gene therapy vector carries a DNA molecule that includes sequences for expressing ⁇ -MSH and/or its derivatives in the host cells.
• gene sequences for ⁇ -MSH and/or its derivatives may be cloned into viral vectors or expression plasmid vectors.
• Constitutive promoters such as cytomegalovirus (CMV) promoter or inducible promoters may drive their expression.
• the inducible promoter employs the use of inflammatory gene promoters such as the interleukins, in particular, the IL-6 promoter, or the complement system gene promoters.
• inflammatory gene promoters include promoters for TNF- ⁇ or the NF-i B response element.
• the gene therapy vector carrying the ⁇ -MSH and/or its derivatives may also carry the appropriate therapeutic gene or nucleic acid of interest. This localizes the expression of ⁇ -MSH and/or its derivatives to the area expressing the therapeutic gene of interest. The local effect of ⁇ -MSH and/or its derivatives may inliibit a local inflammatory response without compromising the systemic immune system of the host. It may also protect the cells that have incorporated the gene therapy vectors from the inflammatory cytotoxic killings of neutrophils or T-cells.
• cloning the gene for ⁇ -MSH and/or its derivatives and associated promoter in the same DNA vector carrying the therapeutic gene of interest may achieve this co-localization effect.
• the ⁇ -MSH and/or its derivatives can be expressed with an internal ribosomal entry site (IRES).
• IRES sequence may be placed between the therapeutic gene and the gene for ⁇ -MSH and/or its derivatives.
• the two genes may be transcribed as a bicistronic mRNA transcript from a single promoter, and the bicistronic mRNA, in turn, may be translated simultaneously at the 5' end and at the IRES sequence.
• IRES sequences and vectors can be commercially obtained, for example, from Clontech Laboratories, Palo Alto, California (pIRES, cat# 6028-1).
• a secretion signal peptide cloned upstream of the gene for ⁇ -MSH and/or its derivatives may also transport ⁇ -MSH and/or its derivatives to the extracellular environment where they are needed.
• secretion peptide signal include the signal peptides for epidermal growth factor, basic fibroblast growth factors, or interleukin-6.
• ⁇ -MSH is an ancient thirteen amino-acid peptide, SYSMEHFRWGKPN ( ⁇ -MSH (1-13)), that is produced by post-translational processing of the larger precursor molecule propiomelanocortin. It shares the 1-13 amino acid sequence with adrenocorticotropic hormone (“ACTH”), also derived from propiomelanocortin.
• ACTH adrenocorticotropic hormone
• ⁇ -MSH is known to be secreted by many cell types including pituitary cells, monocytes, melanocytes, and keratinocytes.
• ⁇ -MSH and its derivatives are known to have potent antipyretic and anti- inflammatory properties, yet they have extremely low toxicity. They can reduce production of host cells' proinflammatory mediators in vitro, and can also reduce production of local and systemic reactions in animal models for inflammation.
• the "core" ⁇ -MSH sequence (4-10) for example, has learning and memory behavioral effects but little antipyretic and anti-inflammatory activity.
• the active message sequence for the antipyretic and anti-inflammatory activities resides in the C-terminal amino-acid sequence of ⁇ -MSH, that is, lysine-proline-valine ("Lys-Pro-Nal" or "KPN").
• ⁇ -MSH lysine-proline-valine
• KPN lysine-proline-valine
• This tripeptide has activities in vitro and in vivo that parallel those of the parent molecule.
• the anti-inflammatory activity of ⁇ -MSH and/or its derivatives are disclosed in the following two patents and references, which are hereby incorporated by reference as if fully set forth the herein: U.S. Patent No. 5,028,592, issued on My 2, 1991 to Lipton, J.M.. entitled Antipyretic and Anti-inflammatory Lys Pro Nal Compositions and Method of Use; U.S. Patent No.
• ⁇ -MSH derivatives include, but are not limited to, peptides with the amino-acid sequence KPN ( ⁇ -MSH (11-13)), MEHFRWG ( ⁇ -MSH (4-10)), or HFRWGKPN ( ⁇ - MSH (6-13)). These derivatives may also include homodimers or heterodimers of the above peptides, which may be achieved by adding cysteine residues at the ⁇ termini of any of the above polypeptides and allowing the cysteines of two polypeptides to form a disulfide bond. The peptides may also be ⁇ -acetylated and/or C-amidated.
• Substituting or deleting certain amino acid residues may also create biologically functional derivatives without altering the effectiveness of the peptides.
• stabilization of the ⁇ -MSH sequence can greatly increase the activity of the peptide and that substitution of D-amino acid forms for L-forms can improve or decrease the effectiveness of the peptides.
• a stable analog of ⁇ -MSH, [ ⁇ le 4 ,D-Phe 7 ] - ⁇ -MSH, which is l ⁇ iown to have marked biological activity on melanocytes and melanoma cells, is approximately ten times more potent than the parent peptide in reducing fever.
• Biological functional equivalents can also be obtained by substitution of amino acids having similar hydropathic values.
• isoleucine and leucine which have a hydropathic index +4.5 and +3.8, respectively, can be substituted for valine, which has a hydropathic index of +4.2, and a protein having like biological activity can still be obtained.
• lysine (-3.9) can be substituted for arginine (-4.5), and so on.
• amino acids can be successfully substituted where such amino acid has a hydropathic score of within about +/- 1 hydropathic index unit of the replaced amino acid.
• ⁇ -MSH and/or its derivatives in conjunction with gene therapy.
• Preparation and purification of ⁇ -MSH and/or its derivatives may employ conventional solid-phase peptide synthesis and reversed-phased high-performance liquid- chromatography techniques.
• Patients who will undergo gene therapy may receive a pharmacologically effective amount of ⁇ -MSH and/or its derivatives either through injections or oral administration.
• the injections for example, can be performed intravenously, intraperitionally, or intradermally depending on the specific location targeted by the gene therapy.
• the patient can then receive a pharmacologically effective amount of the gene therapy vector containing the therapeutic gene or nucleic acid of interest according to conventional gene therapy protocols. If needed, additional administration of ⁇ -MSH and/or its derivatives may be given following the administration of the gene therapy vector.
• the delivery cocktail for the gene therapy vector may include a pharmacologically effective amount of ⁇ -MSH and/or its derivatives that is concurrently or simultaneously administered to the patients.
• This example illustrates the construction of gene therapy vector that expresses ⁇ - MSH and/or its derivatives.
• Preparation and purification of gene sequences that express ⁇ -MSH and/or its derivatives may use, among other techniques, conventional oligonucleotide synthesis techniques.
• Complementary oligonucleotides can be made and annealed to form double stranded DNA molecules capable of being cloned. Additional sequences representing appropriate restriction enzyme sites may be engineered at the ends of each oligonucleotide.
• the oligonucleotide sequence downstream of the ⁇ -MSH sequences includes a stop codon (TAG).
• a fragment corresponding to the signal peptide of IL-6 cDNA may be synthesized, cloned into a vector such as pBluescript KS (Stratagene, San Diego, CA).
• promoter regions for IL-6 or NF- ⁇ B may also be synthesized using oligonucleotides with appropriate matching restriction enzyme sites and cloned upstream of the pBluescript carrying signal sequence.
• ⁇ -MSH or its derivatives sequences may be ligated to the signal sequence and the promoter.
• the oligonucleotides sequence above may include such a sequence or it can be incorporated into PCR primers and linked by conventional PCR techniques.
• the ⁇ -MSH and/or its derivatives may be cloned into the pIRES vector from Clontech Laboratories. Multiple ⁇ - MSH and/or its derivatives may be constructed with multiple IRES sequence if so desired.
• An effective amount of the expression plasmid containing these constructs and the therapeutic gene of interest can be directly injected or introduced into patients using non- viral vectors such as liposomes, electroporation, or using a gene gun.
• the ⁇ -MSH and/or its derivatives constructs can be inserted into appropriate replication deficient retroviral, lentiviral, adenoviral, or adenovirus-associated- viral vectors using standard restriction enzyme and ligation techniques, blunt end cloning, or PCR techniques.
• Packaging cell lines using helper viruses may then package the vector DNA into viral particles for use in gene therapy.
• Titer of the recombinant virus may first be determined, and appropriate amount of viral particles may be introduced into the patients or hosts. It is understood that the viral vector may already contain a therapeutic gene or nucleic acid in addition to ⁇ -MSH and/or its derivatives.
• the cells may express ⁇ -MSH and/or its derivatives, which in turn, inhibits inflammation.
• ⁇ -MSH The anti-inflammatory effect of ⁇ -MSH expression in cells through inhibition of NF- ⁇ B activation have been reported in Ichiyama, et. al., Autocrine a-Melanocyte-Stimulating Hormone Inhibits NF- ⁇ B Activation in Human Glioma, J. Neurosci. Res. 58:684-689 (1999), and is hereby incorporated by reference as if fully set forth herein.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biotechnology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Saccharide Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22741073

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Citations (3)

Family Cites Families (3)

• 2001
  • 2001-04-27 WO PCT/US2001/013826 patent/WO2001082699A1/en not_active Application Discontinuation
  • 2001-04-27 CA CA002406755A patent/CA2406755A1/en not_active Abandoned
  • 2001-04-27 AU AU2001257420A patent/AU2001257420A1/en not_active Abandoned
  • 2001-04-27 JP JP2001579591A patent/JP2004509065A/ja active Pending
  • 2001-04-27 CN CN01808571A patent/CN1429073A/zh active Pending
  • 2001-04-27 EP EP01930932A patent/EP1280409A4/en not_active Withdrawn

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events